Influenza vaccine development
4 European H2020 organizations list this as part of their work — 1 as their primary capability.
Most active in this area
- COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
India's largest public research network, bringing water purification, vaccine delivery, and field-testing capacity to EU-India collaborative projects.
“INDIGO and ENDFLU projects cover next-generation influenza vaccines including needle-free intradermal patches, microneedle delivery, and recombinant protein-based constructs through Phase 1 clinical trials.”
IN7 projects - EXPRES2ION BIOTECHNOLOGIES APS
Danish biotech SME providing recombinant protein and virus-like particle technology for vaccine development against malaria, influenza, and coronaviruses.
“INDIGO project focuses on recombinant HA production, HA deletion mutants, and needle-free intradermal delivery — their largest single grant at EUR 610K.”
SMEDK4 projects - INDIAN INSTITUTE OF SCIENCE
India's top research university contributing energy systems, advanced materials, and vaccine expertise to large EU consortia as an international partner.
“ENDFLU project involves preclinical development and clinical trial work on next-generation influenza vaccines including protein-based and MVA-based constructs.”
IN4 projects - VISMEDERI SRL
Italian SME providing specialized serological testing and immunogenicity assays for vaccine development, with growing expertise in novel delivery systems.
“INDIGO focuses on affordable flu vaccines with novel delivery (microneedle patches, intradermal), and Inno4Vac on accelerating vaccine manufacture.”
PrimarySMEIT3 projects